Journal Mobile Options
Table of Contents
Vol. 18, No. 2, 2004
Issue release date: August 2004
Section title: Original Research Article
Dement Geriatr Cogn Disord 2004;18:165–171
(DOI:10.1159/000079197)

Autoimmune Responses to Amyloid Structures of Aβ(25–35) Peptide and Human Lysozyme in the Serum of Patients with Progressive Alzheimer’s Disease

Gruden M.A.a · Davudova T.B.b · Mališauskas M.f · Zamotin V.V.f · Sewell R.D.E.e · Voskresenskaya N.I.c · Kostanyan I.A.d · Sherstnev V.V.a · Morozova-Roche L.A.f
aP.K. Anokhin Institute of Normal Physiology, RAS, bInstitute of General Pathology and Pathophysiology, cState Scientific Center of Psychiatric Health RAMS, and dM.M. Shemykin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, RAS, Moscow, Russia; eWelsh School of Pharmacy, Cardiff University, Cardiff, UK; fDepartment of Medical Biochemistry and Biophysics, Umeå University, Umeå, Sweden

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Research Article

Received: 1/30/2004
Published online: 8/13/2004
Issue release date: August 2004

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 2

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: http://www.karger.com/DEM

Abstract

We have found an increased level of serum antibodies to the prefibrillar structures of both Aβ(25–35) peptide and human lysozyme in Alzheimer’s disease (AD) patients compared to age-matched controls, indicating that autoimmunity is implicated in AD. In the serum of AD patients with a long-term duration (>15 years) the titer of serum antibodies to aggregates of Aβ(25–35) peptide increased by approximately 5-fold, whilst the antibody titer to lysozyme protofilaments decreased by approximately 8-fold compared to patients with AD duration of <5 years. The content of immunoglobulins of the A, G and M types declined, particularly in AD duration of >15 years. An increase in the concentration of immune complexes and higher lysozyme activity was detected in the serum of all patients and this was suggestive of an inflammatory reaction. We propose that the autoimmune response to different amyloid structures in AD can be viewed as a clearance pathway targeting amyloid development. Autoimmune response can be exploited as a marker of ongoing protein aggregation and hence be used as a diagnostic feature of AD.

© 2004 S. Karger AG, Basel


  

Author Contacts

L.A. Morozova-Roche
Department of Medical Biochemistry and Biophysics, Umeå University
SE–901 87 Umeå (Sweden)
Tel. +46 90 786 5283, Fax +46 90 786 9795
E-Mail ludmilla.morozova-roche@chem.umu.se

  

Article Information

Accepted: January 30, 2004
Published online: June 21, 2004
Number of Print Pages : 7
Number of Figures : 1, Number of Tables : 2, Number of References : 36

  

Publication Details

Dementia and Geriatric Cognitive Disorders

Vol. 18, No. 2, Year 2004 (Cover Date: Released August 2004)

Journal Editor: V. Chan-Palay, New York, N.Y.
ISSN: 1420–8008 (print), 1421–9824 (Online)

For additional information: http://www.karger.com/journals/dem


Article / Publication Details

First-Page Preview
Abstract of Original Research Article

Received: 1/30/2004
Published online: 8/13/2004
Issue release date: August 2004

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 2

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: http://www.karger.com/DEM


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.